Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma

Papers of special note have been highlighted as: • of interest

References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
  MedlineGoogle Scholar
• 2 Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C et al. Global, regional and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 3(4), 524–548 (2017).
  MedlineGoogle Scholar
• 3 Moreau P. How I treat myeloma with new agents. Blood 130(13), 1507–1513 (2017).
  Medline CASGoogle Scholar
• 4 Moreau P, San Miguel J, Sonneveld P et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(Suppl. 4), iv52–iv61 (2017).
  Medline CASGoogle Scholar
• 5 Spicka I, Ocio EM, Oakervee HE et al. Randomized Phase III study (ADMYRE) of plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma. Blood 130, 1886 (2017). • Includes the most recent Phase III data in multiple myeloma.
  Google Scholar
• 6 Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. Am. Soc. Clin. Oncol. Educ. Book 2014, 199–203 (2014).
  Google Scholar
• 7 ClinicalTrials.gov.com (2018). www.clinicaltrials.gov.
  Google Scholar
• 8 Lee L, Bounds D, Paterson J et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174(6), 911–922 (2016).
  Medline CASGoogle Scholar
• 9 Rinehart KL Jr, Gloer JB, Hughes RG Jr et al. Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate. Science 212(4497), 933–935 (1981).
  Medline CASGoogle Scholar
• 10 Crampton SL, Adams EG, Kuentzel SL, Li LH, Badiner G, Bhuyan BK. Biochemical and cellular effects of didemnins A and B. Cancer Res. 44(5), 1796–1801 (1984).
  Medline CASGoogle Scholar
• 11 Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1α. J. Biol. Chem. 269(22), 15411–15414 (1994).
  Medline CASGoogle Scholar
• 12 Shin DM, Holoye PY, Forman A et al. Phase II clinical trial of didemnin B in previously treated small-cell lung cancer. Invest. New Drugs 12(3), 243–249 (1994).
  Medline CASGoogle Scholar
• 13 Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA. Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study. Am. J. Clin. Oncol. 23(3), 273–277 (2000).
  Medline CASGoogle Scholar
• 14 Sakai R, Rinehart KL, Kishore V et al. Structure–activity relationships of the didemnins. J. Med. Chem. 39(14), 2819–2834 (1996).
  Medline CASGoogle Scholar
• 15 Humeniuk R, Menon LG, Mishra PJ et al. Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in aplidin-induced cytotoxicity. Leukemia 21(12), 2399–2405 (2007).
  Medline CASGoogle Scholar
• 16 Losada A, Munoz-Alonso MJ, Garcia C et al. Translation elongation factor eEF1A2 is a novel anticancer target for the marine natural product plitidepsin. Sci. Rep. 6, 35100 (2016). • Contains recent insights into the mechanism of action of plitidepsin.
  Medline CASGoogle Scholar
• 17 Chang R, Wang E. Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J. Cell. Biochem. 100(2), 267–278 (2007).
  Medline CASGoogle Scholar
• 18 Sun Y, Du C, Wang B, Zhang Y, Liu X, Ren G. Upregulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer. Biochem. Biophys. Res. Commun. 450(1), 1–6 (2014).
  Medline CASGoogle Scholar
• 19 Hotokezaka Y, Tobben U, Hotokezaka H et al. Interaction of the eukaryotic elongation factor 1A with newly synthesized polypeptides. J. Biol. Chem. 277(21), 18545–18551 (2002).
  Medline CASGoogle Scholar
• 20 Li Z, Qi CF, Shin DM et al. Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas. PLoS ONE 5(5), e10755 (2010).
  MedlineGoogle Scholar
• 21 Garcia-Fernandez LF, Losada A, Alcaide V et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 21(49), 7533–7544 (2002).
  Medline CASGoogle Scholar
• 22 Cuadrado A, Garcia-Fernandez LF, Gonzalez L et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J. Biol. Chem 278(1), 241–250 (2003).
  Medline CASGoogle Scholar
• 23 Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A. JNK activation is critical for aplidin-induced apoptosis. Oncogene 23(27), 4673–4680 (2004).
  Medline CASGoogle Scholar
• 24 Gonzalez-Santiago L, Suarez Y, Zarich N et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation and MKP-1 phosphatase downregulation. Cell Death Differ. 13(11), 1968–1981 (2006).
  Medline CASGoogle Scholar
• 25 Chauhan D, Li G, Hideshima T et al. JNK-dependent release of mitochondrial protein, smac, during apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 278(20), 17593–17596 (2003).
  Medline CASGoogle Scholar
• 26 Gajate C, An F, Mollinedo F. Rapid and selective apoptosis in human leukemic cells induced by aplidine through a Fas/CD95- and mitochondrial-mediated mechanism. Clin. Cancer Res. 9(4), 1535–1545 (2003).
  Medline CASGoogle Scholar
• 27 Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem. 280(12), 11641–11647 (2005).
  Medline CASGoogle Scholar
• 28 Villunger A, Egle A, Marschitz I et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 90(1), 12–20 (1997).
  Medline CASGoogle Scholar
• 29 Broggini M, Marchini SV, Galliera E et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17(1), 52–59 (2003).
  Medline CASGoogle Scholar
• 30 Taraboletti G, Poli M, Dossi R et al. Antiangiogenic activity of aplidine, a new agent of marine origin. Br. J. Cancer 90(12), 2418–2424 (2004).
  Medline CASGoogle Scholar
• 31 Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann. Oncol. 16(10), 1667–1674 (2005).
  Medline CASGoogle Scholar
• 32 Straight AM, Oakley K, Moores R et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother. Pharmacol. 57(1), 7–14 (2006).
  Medline CASGoogle Scholar
• 33 Morande PE, Zanetti SR, Borge M et al. The cytotoxic activity of aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells. Invest. New Drugs 30(5), 1830–1840 (2012).
  Medline CASGoogle Scholar
• 34 Mitsiades CS, Ocio EM, Pandiella A et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 68(13), 5216–5225 (2008). • Contains in vitro experiments with plitidepsin in multiple myeloma.
  Medline CASGoogle Scholar
• 35 Losada A, Lopez-Oliva JM, Sanchez-Puelles JM, Garcia-Fernandez LF. Establishment and characterisation of a human carcinoma cell line with acquired resistance to aplidin. Br. J. Cancer 91(7), 1405–1413 (2004).
  Medline CASGoogle Scholar
• 36 Gonzalez-Santiago L, Alfonso P, Suarez Y et al. Proteomic analysis of the resistance to aplidin in human cancer cells. J. Proteome Res. 6(4), 1286–1294 (2007).
  Medline CASGoogle Scholar
• 37 Izquierdo MA, Bowman A, Garcia M et al. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-h weekly intravenous infusion in patients with advanced solid tumors. Clin. Cancer Res. 14(10), 3105–3112 (2008).
  Medline CASGoogle Scholar
• 38 van Andel L, Rosing H, Tibben MM et al. Metabolite profiling of the novel anticancer agent, plitidepsin, in urine and faeces in cancer patients after administration of (14) C-plitidepsin. Cancer Chemother. Pharmacol. (2018) (Epub ahead of print).
  Google Scholar
• 39 Faivre S, Chieze S, Delbaldo C et al. Phase I and pharmacokinetic study of Aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J. Clin. Oncol. 23(31), 7871–7880 (2005). • First in human trial of plitidepsin.
  Medline CASGoogle Scholar
• 40 Maroun JA, Belanger K, Seymour L et al. Phase I study of aplidine in a dailyx5 1-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann. Oncol. 17(9), 1371–1378 (2006).
  Medline CASGoogle Scholar
• 41 Ciruelos EM TC, Dominguez MJ, Twelves T et al. Phase I clinical and pharmacokinetic study of the marine compound aplidin (APL) administered as a 3-hour infusion every 2 weeks. Proc. Am. Soc. Clin. Oncol. 21, Abstract 422 (2002).
  Google Scholar
• 42 Anthoney A P-AL, Twelves C. Phase I and pharmacokinetic (PK) study of aplidin (APL) using a 24-hour weekly schedule. Proc. Am. Soc. Clin. Oncol. 19, Abstract 734 (2000).
  Google Scholar
• 43 Peschel C, Hartmann JT, Schmittel A et al. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 60(3), 374–380 (2008).
  MedlineGoogle Scholar
• 44 Schoffski P, Guillem V, Garcia M et al. Phase II randomized study of plitidepsin (aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar. Drugs 7(1), 57–70 (2009).
  Medline CASGoogle Scholar
• 45 Eisen T, Thatcher N, Leyvraz S et al. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer 64(1), 60–65 (2009).
  MedlineGoogle Scholar
• 46 Eisen T, Thomas J, Miller WH Jr et al. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res. 19(3), 185–192 (2009).
  Medline CASGoogle Scholar
• 47 Dumez H, Gallardo E, Culine S et al. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar. Drugs 7(3), 451–463 (2009).
  Medline CASGoogle Scholar
• 48 Baudin E, Droz JP, Paz-Ares L, van Oosterom AT, Cullell-Young M, Schlumberger M. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. Am. J. Clin. Oncol. 33(1), 83–88 (2010).
  Medline CASGoogle Scholar
• 49 Pardanani A, Tefferi A, Guglielmelli P et al. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a Phase II clinical trial. Blood Cancer J. 5, e286 (2015).
  Medline CASGoogle Scholar
• 50 Toulmonde M, Le Cesne A, Piperno-Neumann S et al. Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group single-arm Phase II study. Ann. Oncol. 26(7), 1465–1470 (2015).
  Medline CASGoogle Scholar
• 51 Ribrag V, Caballero D, Ferme C et al. Multicenter Phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica 98(3), 357–363 (2013).
  Medline CASGoogle Scholar
• 52 Salazar R, Plummer R, Oaknin A et al. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas. Invest. New Drugs 29(6), 1406–1413 (2011).
  Medline CASGoogle Scholar
• 53 Aspeslagh S, Awada A, A SM-P et al. Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors. Anticancer Drugs 27(10), 1021–1027 (2016).
  Medline CASGoogle Scholar
• 54 Mateos MV, Cibeira MT, Richardson PG et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin. Cancer Res. 16(12), 3260–3269 (2010). • The first Phase II trial in MM.
  Medline CASGoogle Scholar
• 55 Plummer R, Lorigan P, Brown E et al. Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. Br. J. Cancer 109(6), 1451–1459 (2013).
  Medline CASGoogle Scholar
• 56 Aspeslagh S, Stein M, Bahleda R et al. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anticancer Drugs 28(3), 341–349 (2017).
  Medline CASGoogle Scholar
• 57 Wieser T, Deschauer M, Olek K, Hermann T, Zierz S. Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients. Neurology 60(8), 1351–1353 (2003).
  Medline CASGoogle Scholar
• 58 Latimer NR, Abrams KR, Lambert PC et al. Adjusting survival time estimates to account for treatment switching in randomized controlled trials: an economic evaluation context: methods, limitations and recommendations. Med. Decis. Making 34(3), 387–402 (2014).
  MedlineGoogle Scholar
• 59 Geldof AA, Mastbergen SC, Henrar RE, Faircloth GT. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother. Pharmacol. 44(4), 312–318 (1999).
  Medline CASGoogle Scholar
• 60 Gómez S. In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp. Hematol. 31(11), 1104–1111 (2003).
  Medline CASGoogle Scholar
• 61 Albella B, Faircloth G, Lopez-Lazaro L, Guzman C, Jimeno J, Bueren JA. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. Comparison with the clinical results. Eur. J. Cancer 38(10), 1395–1404 (2002).
  Medline CASGoogle Scholar
• 62 Le Tourneau C, Raymond E, Faivre S. Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr. Pharm. Des. 13(33), 3427–3439 (2007).
  Medline CASGoogle Scholar
• 63 Soto-Matos A, Szyldergemajn S, Extremera S et al. Plitidepsin has a safe cardiac profile: a comprehensive analysis. Mar. Drugs 9(6), 1007–1023 (2011).
  Medline CASGoogle Scholar
• 64 European Medicines Agency (2018). www.ema.europa.eu.
  Google Scholar
• 65 Miguel JS, Weisel K, Moreau P et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, Phase III trial. Lancet Oncol. 14(11), 1055–1066 (2013).
  Medline CASGoogle Scholar